Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter StudyUna Kjällquist, Johan Hartman, Maria Ekholm et al.|Cancers|2022Cited by 21
PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).Renske Kornalijnslijper-Altena, Jonas Bergh, Anne Andersson et al.|Journal of Clinical Oncology|2020Cited by 0
Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter studyUna Kjällquist, Alexios Matikas, Nikolaos Tsiknakis et al.|Research Square|2024Cited by 0